Contineum Therapeutics (CTNM) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 26, 2026, with voting available online, by phone, mail, or during the meeting via webcast.

• Stockholders of record as of April 27, 2026, are eligible to vote on the proposals.

• Proxy materials and the 2025 Annual Report are primarily distributed via the internet, with paper copies available upon request.

Voting matters and shareholder proposals

• Stockholders will vote on electing three Class II directors (Evert Schimmelpennink, Lori M. Lyons-Williams, Diego Miralles, M.D.) to serve until 2029.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.

• Shareholder proposals for the 2027 meeting must be submitted by January 15, 2027, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of eight directors divided into three classes with staggered terms.

• A majority of directors are independent, with only the CEO and Dr. Miralles considered non-independent.

• The board has audit, compensation, and nominating/governance committees, all composed entirely of independent directors.

• The chairperson role is separated from the CEO to reinforce board independence.

• Corporate governance guidelines and a code of conduct are in place and available on the company website.